RGLS Relative Valuation
RGLS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RGLS is overvalued; if below, it's undervalued.
Historical Valuation
Regulus Therapeutics Inc (RGLS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 597.39. The fair price of Regulus Therapeutics Inc (RGLS) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：7.85
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
6.73
P/B
Median3y
1.01
Median5y
1.52
-7.74
FCF Yield
Median3y
-76.88
Median5y
-67.27
Competitors Valuation Multiple
The average P/S ratio for RGLS's competitors is 0.73, providing a benchmark for relative valuation. Regulus Therapeutics Inc Corp (RGLS) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Regulus Therapeutics Inc (RGLS) currently overvalued or undervalued?
What is Regulus Therapeutics Inc (RGLS) fair value?
How does RGLS's valuation metrics compare to the industry average?
What is the current P/B ratio for Regulus Therapeutics Inc (RGLS) as of May 04 2025?
What is the current FCF Yield for Regulus Therapeutics Inc (RGLS) as of May 04 2025?
What is the current Forward P/E ratio for Regulus Therapeutics Inc (RGLS) as of May 04 2025?